Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Robertson, Michael J., Kahl, Brad S., Vose, Julie M., de Vos, Sven, Laughlin, Mary, Flynn, Patrick J., Rowland, Kendrith, Cruz, Jose C., Goldberg, Stuart L., Musib, Luna, Darstein, Christelle, Enas, Nathan, Kutok, Jeffery L., Aster, Jon C., Neuberg, Donna, Savage, Kerry J., LaCasce, Ann, Thornton, Donald, Slapak, Christopher A., Shipp, Margaret A.·2007·Journal of Clinical Oncology

Abstract

Purpose: Protein kinase C beta (PKCβ) was identified by gene-expression profiling, preclinical evaluation, and independent immunohistochemical analysis as a rational therapeutic target in diffuse large B-cell lymphoma (DLBCL). We conducted a multicenter phase II study of a potent inhibitor of PKCβ, enzastaurin, in patients with relapsed or refractory DLBCL. Patients and Methods: Enzastaurin was taken orally once daily until disease progression or unacceptable toxicity occurred. Study end points included freedom from progression (FFP) for ≥ two cycles (one cycle = 28 days), objective response, and toxicity. Results: Fifty-five patients (median age, 68 years) were enrolled. Patients had received a median number of two prior therapies (range, one to five); six patients relapsed after high-dose therapy and autologous stem-cell transplantation. Only one grade 4 toxicity (hypomagnesemia) occurred. Grade 3 toxicities included fatigue (n = 2), edema (n = 1), headache (n = 1), motor neuropathy (n = 1), and thrombocytopenia (n = 1). No grade 3 or 4 neutropenia occurred. No deaths or discontinuations due to toxicity were reported. Fifteen patients completed less than one cycle of therapy. Twelve of 55 patients (22%; 95% CI, 13% to 46%) experienced FFP for ≥ two cycles, and eight patients remained free from progression for ≥ four cycles (15%; 95% CI, 6% to 27%). Four patients (7%; 95% CI, 2% to 18%), including three complete responders and one patient with stable disease, continue to experience FFP 20+ to 50+ months after study entry. Conclusion: Treatment with enzastaurin was well-tolerated and associated with prolonged FFP in a small subset of patients with relapsed or refractory DLBCL. Further studies of enzastaurin in DLBCL are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.09.3146

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 232

Metadata

Authors
Robertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., Darstein, C., Enas, N., Kutok, J. L., Aster, J. C., Neuberg, D., Savage, K. J., LaCasce, A., Thornton, D., Slapak, C. A., & Shipp, M. A.
Venue
Journal of Clinical Oncology
Published
2007-05-01
Volume
25
Issue
13
Pages
1741-1746
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2120601121
Cited by
232
References
1
FWCI
16.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2006.09.3146
The paper
Robertson, M. J., Kahl, B. S., Vose, J. M., de Vos, S., Laughlin, M., Flynn, P. J., Rowland, K., Cruz, J. C., Goldberg, S. L., Musib, L., Darstein, C., Enas, N., Kutok, J. L., Aster, J. C., Neuberg, D., Savage, K. J., LaCasce, A., Thornton, D., Slapak, C. A., & Shipp, M. A. (2007). Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.09.3146

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.